Unlearn, an AI company, showcased the impact of its technology in two poster sessions at the Alzheimer’s Association International Conference. Their Digital Twin Generators create personalized forecasts of clinical outcomes for participants, enhancing the efficiency of clinical trials.
Unlearn’s Digital Twin Generators have demonstrated significant benefits in Phase III clinical trials for mild-to-moderate Alzheimer’s Disease (AD):
• Reduced control arm sizes by 33% when estimating treatment effects on cognitive impairment (ADAS-Cog11) at 18 months.
• Reduced control arm sizes by 19% when estimating treatment effects on functional impairment (CDR-SB) at 12 months.
In Phase 2 studies, Unlearn’s technology can:
• Reduce overall sample sizes by 10-15% when estimating treatment effects on functional impairment (CDR-SB) at week 96.
• Increase statistical power by up to 7% (80% to 87%) when estimating treatment effects on cognitive impairment (ADAS-Cog11).
Unlearn’s Digital Twin Generators offer several advantages for clinical trials. By incorporating personalized forecasts into trial designs, researchers can:
• Increase power and reduce sample sizes, saving time and resources.
• Optimize resource allocation by reducing the need for large control groups.
• Enhance the sensitivity of clinical trials, allowing for more precise detection of treatment effects.
Unlearn’s technology revolutionizes clinical development, enabling pharmaceutical and biotech companies to streamline trials, accelerate drug discovery, and produce reliable outcomes more efficiently.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Ferry, a computer data scientist, focuses on the latest clinical trial industry news and trends.
